Parameter
| Biomarker | Claudin18.2 (tight junction protein 18.2) | Full name | Claudin-18 splice variant 2 | Molecular Type | Proteins |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, Prediction | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Tumor tissue (IHC), Circulating tumor cells (CTC, flow cytometry) | ||
| Pathobiological Mechanisms | Claudin18.2 protein is normally expressed in differentiated gastric mucosal epithelial cells, and about 30%-40% of gastric cancers have claudin18.2 protein overexpression, which promotes tumor invasion by maintaining tight junctions between tumor cells. Claudin18.2 is the target of CAR-T cell therapy and antibody drug conjugate (ADC) | ||||
| Clinical Availability Status | Clinical research stage: Claudin18.2 CAR-T (such as CT041) is in phase II clinical practice, and ADC drugs are in phase I clinical practice | ||||
| Notes and Dynamics | The popular marker of new targeted therapy for gastric cancer has high safety and limited expression in normal tissues (only gastric mucosa). It has a significant effect on patients with diffuse gastric cancer and peritoneal metastasis. Combined immunotherapy can enhance the anti-tumor effect, which is a new hope for the refractory population of advanced gastric cancer | ||||